Together, our results indicate that a short course of denosumab enhances immune infiltration as determined by the increased levels of TILs, B and T lymphocytes, and CD4+ and CD8+ T cells in luminal and HER2+ breast tumors, validating the clinical relevance of the findings in the preclinical models. The gene discussed is CD4; the disease is breast neoplasm.